Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Go back to Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial| CONATUS PHARMACEUT (NASDAQ: CNAT) | Delayed: 0.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.56 | 52 Week High | $4.05 | |||
| Open | $48.51 | 52 Week Low | $1.40 | |||
| Day High | $0.56 | P/E | N/A | |||
| Day Low | $0.56 | EPS | $-0.94 | |||
| Volume | 111,906 | |||||
